BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16793840)

  • 1. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis.
    van der Laken CJ; Voskuyl AE; Roos JC; Stigter van Walsum M; de Groot ER; Wolbink G; Dijkmans BA; Aarden LA
    Ann Rheum Dis; 2007 Feb; 66(2):253-6. PubMed ID: 16793840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The formation of infliximab and anti-infliximab immune complexes as an explanation for non-responding to infliximab treatment of rheumatoid arthritis: observational study in 4 patients].
    van der Laken CJ; Voskuyl AE; Roos JC; Stigter van Walsum M; de Groot ER; Wolbink GJ; Dijkmans BA; Aarden LA
    Ned Tijdschr Geneeskd; 2008 Jul; 152(30):1672-7. PubMed ID: 18714521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab.
    Allanore Y; Sellam J; Batteux F; Job Deslandre C; Weill B; Kahan A
    Clin Exp Rheumatol; 2004; 22(6):756-8. PubMed ID: 15638051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure.
    Krintel SB; Grunert VP; Hetland ML; Johansen JS; Rothfuss M; Palermo G; Essioux L; Klause U
    Rheumatology (Oxford); 2013 Jul; 52(7):1245-53. PubMed ID: 23459699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.
    Pascual-Salcedo D; Plasencia C; Ramiro S; Nuño L; Bonilla G; Nagore D; Ruiz Del Agua A; Martínez A; Aarden L; Martín-Mola E; Balsa A
    Rheumatology (Oxford); 2011 Aug; 50(8):1445-52. PubMed ID: 21427177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-TNF scintigraphy to assess TNF-α-associated joint inflammation in rheumatoid arthritis and osteoarthritis.
    Hermann J; Lipp RW; Dunzinger A; Spreizer C; Schaffler G; Kvaternik H; Ofner P; Graninger W
    Clin Exp Rheumatol; 2014; 32(4):614. PubMed ID: 24959905
    [No Abstract]   [Full Text] [Related]  

  • 10. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
    Wolbink GJ; Voskuyl AE; Lems WF; de Groot E; Nurmohamed MT; Tak PP; Dijkmans BA; Aarden L
    Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of autoantibodies during prolonged treatment with infliximab.
    Louis M; Rauch J; Armstrong M; Fitzcharles MA
    J Rheumatol; 2003 Dec; 30(12):2557-62. PubMed ID: 14719194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy.
    Mori S
    Mod Rheumatol; 2007; 17(2):83-91. PubMed ID: 17437161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of neutrophil function by plasma of rheumatoid arthritis patients treated with infliximab.
    Dain L; Braun-Moscovici Y; Baum E; Nahir AM; Hoffer E
    Clin Exp Rheumatol; 2006; 24(1):38-44. PubMed ID: 16539817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
    Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis.
    Hoshino M; Yoshio T; Onishi S; Minota S
    Mod Rheumatol; 2012 Aug; 22(4):532-40. PubMed ID: 22173229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2007 Jul; 66(7):921-6. PubMed ID: 17301106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
    Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
    Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients.
    Lindberg J; af Klint E; Catrina AI; Nilsson P; Klareskog L; Ulfgren AK; Lundeberg J
    Arthritis Res Ther; 2006; 8(6):R179. PubMed ID: 17134501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
    Lipsky PE; van der Heijde DM; St Clair EW; Furst DE; Breedveld FC; Kalden JR; Smolen JS; Weisman M; Emery P; Feldmann M; Harriman GR; Maini RN;
    N Engl J Med; 2000 Nov; 343(22):1594-602. PubMed ID: 11096166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.